GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
- A1334 Mosapride CitrateTarget: 5-HT3 Receptors|5-HT4 ReceptorsSummary: 5-HT receptor agonist
- A2436 Fluoxetine HClTarget: Serotonin (5-HT) reuptakeSummary: Serotonin reuptake inhibitor,selective
- A5294 Sumatriptan SuccinateTarget: 5-HT1 ReceptorsSummary: 5-HT1 receptor agonist
- B5321 DOI hydrochlorideTarget: 5-HT2 ReceptorsSummary: A brain-permeable 5-HT2A/5-HT2C receptor agonist
- B2240 OlanzapineTarget: 5-HT2 Receptors|D2 ReceptorsSummary: Antagonist of 5-HT2A and dopamine D2 receptors
- B1001 Loxapine1 CitationTarget: 5-HT2 ReceptorsSummary: 5-HT receptor antagonist
- B1477 Lurasidone HClTarget: 5-HT2 Receptors|D2 Receptors|5-HT1 Receptors|5-HT7 ReceptorsSummary: Dopamine D2/5-HT2A/5-HT7/5-HT1A inhibitor
- B1205 FluvoxamineTarget: Serotonin reuptakeSummary: Selective serotonin reuptake inhibitor
- B1206 PizotifenTarget: 5-HT2 ReceptorsSummary: Highly selective 5-HT receptor blocking agent
- B2007 Pizotifen MalateTarget: 5-HT2 Receptors|D2 ReceptorsSummary: 5-HT receptor antagonist